These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25252191)

  • 21. Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?
    Zhao Z; Stephan C; Weickmann S; Jung M; Kristiansen G; Jung K
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapy.
    Bell EH; Kirste S; Fleming JL; Stegmaier P; Drendel V; Mo X; Ling S; Fabian D; Manring I; Jilg CA; Schultze-Seemann W; McNulty M; Zynger DL; Martin D; White J; Werner M; Grosu AL; Chakravarti A
    PLoS One; 2015; 10(3):e0118745. PubMed ID: 25760964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a Novel MicroRNA Panel Associated with Metastasis Following Radical Prostatectomy for Prostate Cancer.
    Nam RK; Wallis CJD; Amemiya Y; Benatar T; Seth A
    Anticancer Res; 2018 Sep; 38(9):5027-5034. PubMed ID: 30194146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The surgical learning curve for prostate cancer control after radical prostatectomy.
    Vickers AJ; Bianco FJ; Serio AM; Eastham JA; Schrag D; Klein EA; Reuther AM; Kattan MW; Pontes JE; Scardino PT
    J Natl Cancer Inst; 2007 Aug; 99(15):1171-7. PubMed ID: 17652279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
    Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
    PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy.
    Mortensen MM; Høyer S; Orntoft TF; Sørensen KD; Dyrskjøt L; Borre M
    BMC Cancer; 2014 Nov; 14():859. PubMed ID: 25416653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer.
    Karatas OF; Guzel E; Suer I; Ekici ID; Caskurlu T; Creighton CJ; Ittmann M; Ozen M
    PLoS One; 2014; 9(6):e98675. PubMed ID: 24967583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
    Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
    Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
    J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The significance of monoamine oxidase-A expression in high grade prostate cancer.
    Peehl DM; Coram M; Khine H; Reese S; Nolley R; Zhao H
    J Urol; 2008 Nov; 180(5):2206-11. PubMed ID: 18804811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy.
    Casanova-Salas I; Rubio-Briones J; Calatrava A; Mancarella C; Masiá E; Casanova J; Fernández-Serra A; Rubio L; Ramírez-Backhaus M; Armiñán A; Domínguez-Escrig J; Martínez F; García-Casado Z; Scotlandi K; Vicent MJ; López-Guerrero JA
    J Urol; 2014 Jul; 192(1):252-9. PubMed ID: 24518785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
    Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
    Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
    Wang XL; Wang YY; He HD; Xie X; Yu ZJ; Pan YM
    Cancer Biomark; 2015; 15(6):799-805. PubMed ID: 26406405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating microRNAs in plasma before and after radical prostatectomy.
    McDonald AC; Raman JD; Shen J; Liao J; Pandya B; Vira MA
    Urol Oncol; 2019 Nov; 37(11):814.e1-814.e7. PubMed ID: 31421994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative Statin Use at the Time of Radical Prostatectomy Is Not Associated With Biochemical Recurrence or Pathologic Upgrading.
    Lyon TD; Turner RM; Yabes JG; Woldemichael E; Davies BJ; Jacobs BL; Nelson JB
    Urology; 2016 Nov; 97():153-159. PubMed ID: 27516122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence.
    Cole AI; Morgan TM; Spratt DE; Palapattu GS; He C; Tomlins SA; Weizer AZ; Feng FY; Wu A; Siddiqui J; Chinnaiyan AM; Montgomery JS; Kunju LP; Miller DC; Hollenbeck BK; Wei JT; Mehra R
    J Urol; 2016 Aug; 196(2):405-11. PubMed ID: 26920466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer.
    Kumar B; Rosenberg AZ; Choi SM; Fox-Talbot K; De Marzo AM; Nonn L; Brennen WN; Marchionni L; Halushka MK; Lupold SE
    Sci Rep; 2018 May; 8(1):7189. PubMed ID: 29739972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radical prostatectomy and positive surgical margins: relationship with prostate cancer outcome.
    De La Roca RL; Da Cunha IW; Bezerra SM; Da Fonseca FP
    Int Braz J Urol; 2014; 40(3):306-15. PubMed ID: 25010296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.